---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-092064"
form_type: "8-K"
ticker: "CYRX"
cik: "0001124524"
company_name: "Cryoport, Inc."
filed_at: "2026-08-06T20:30:48+00:00"
generated_at: "2026-08-06T20:33:26.205458+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cryoport Q2 2026 revenue $49.0M (+8% YoY); achieves positive adjusted EBITDA

## Summary
- Revenue $49.0M, up 8% YoY; Life Sciences Services +15%, BioStorage/BioServices +25%.
- Adjusted EBITDA from continuing operations positive $0.4M vs -$0.9M in Q2 2025.
- Net loss attributable to common stockholders $0.20 per share (vs $2.13 income in Q2 2025, which included divestiture gain).
- Supporting 779 clinical trials and 22 commercial CGT as of June 30, 2026.
- Cash and short-term investments $396.7M; anticipate 11 possible BLA/MAA applications in H2 2026.

## SEC filing metadata
- accession: 0001104659-26-092064
- form_type: 8-K
- ticker: CYRX
- cik: 0001124524
- company_name: Cryoport, Inc.
- filed_at: 2026-08-06T20:30:48+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1124524/000110465926092064/0001104659-26-092064-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1124524/000110465926092064/tm2622464d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-092064
- JSON: https://secwatch.observer/filing/0001104659-26-092064.json
- Plain text: https://secwatch.observer/filing/0001104659-26-092064.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.